Skip to main navigation
logo

Investor Relations

  • Overview
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • News & Events
    • News Releases
    • Investor Calendar
    • Presentations & Publications
  • Financial Information
    • SEC Filings
    • financial and regulatory reports
    • shareholder circular
  • Corporate Governance
    • Governance Overview
    • Leadership
    • Board of Directors
  • Shareholder Services
    • Investor FAQs
    • Email Alerts
    • Contact IR

Presentations & Publications

Corporate Presentations

Corporate Presentation - January 2023
Jan 06, 2023

Data & Congress Presentations

IMP-MEL: A phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC)
November 10, 2022
Source
Presented at SITC 2022
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and NSCLC (IMP-MEL)
October 3, 2022
Source
Presented at ASCO 2022
Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas
July 21, 2022
Source
Presented at ASCO 2021
A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy
July 21, 2022
Source
Presented at ASCO 2021

Publications

Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses
PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

Featured Pages

Stock Information
Financial Information
Contact IR
FAQs

Investor Tools

  • Print Page
  • RSS Feeds
  • Email Page
  • Email Alerts

Copyright © All rights reserved Portage Biotech

Legal Links

Terms of Use  Privacy policy   Disclaimer

  • Facebook
  • Twitter
  • LinkedIn
  • Google+